Confocal fluorescence imaging enables noninvasive quantitative assessment of host cell populations in vivo following photodynamic therapy

Theranostics

Volumn 2, Issue 9, 2012, Pages 840-849

  Mitra, Soumya ^a   Mironov, Oleg ^a   Foster, Thomas H ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Con focal fluorescence microscopy; HPPH; Immune cell imaging; In vivo imaging; Intratumor drug distribution; Photodynamic therapy

Indexed keywords

2 (1 HEXYLOXYETHYL) 2 DEVINYL PYROPHEOPHORBIDE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CD11B ANTIGEN; CELL PROTEIN; FLUORESCENT DYE; GR1 PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CELL DENSITY; CELL LABELING; CELL POPULATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SELECTIVITY; DRUG UPTAKE; EAR TUMOR; FEMALE; FLUORESCENCE IMAGING; IMMUNE RESPONSE; IN VIVO STUDY; INFLAMMATION; IRRADIATION; MOUSE; NEUTROPHIL; NON INVASIVE PROCEDURE; NONHUMAN; PHOTODYNAMIC THERAPY; QUANTITATIVE ANALYSIS; TISSUE PERFUSION; TREATMENT RESPONSE;

EID: 84872426081     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.4385     Document Type: Article

References (34)

1. Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011; 61: 250-81.
2. Harrod-Kim P. Tumor ablation with photodynamic therapy: introduction to mechanism and clinical applications. J Vasc Interv Radiol. 2006; 17: 1441-8.
3. Brown SB, Brown EA, Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol. 2004; 5: 497-508.
4. Bellnier DA, Greco WR, Loewen GM, Nava H, Oseroff AR, Pandey RK, et al. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients. Cancer Res. 2003; 63: 1806-13.
5. Nava HR, Allamaneni SS, Dougherty TJ, Cooper MT, Tan W, Wilding G, et al. Photodynamic therapy (PDT) using HPPH for the treatment of precancerous lesions associated with barrett's esophagus. Lasers Surg Med. 2011; 43: 705-12.
6. Sunar U, Rohrbach D, Rigual N, Tracy E, Keymel K, Cooper MT, et al. Monitoring photobleaching and hemodynamic responses to HPPH-mediated photodynamic therapy of head and neck cancer: a case report. Opt Express. 2010; 18: 14969-78.
7. Bellnier DA, Greco WR, Nava H, Loewen GM, Oseroff AR, Dougherty TJ. Mild skin photosensitivity in cancer patients following injection of Photochlor (2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a; HPPH) for photodynamic therapy. Cancer Chemother Pharmacol. 2006; 57: 40-5.
8. Payne JT, McCaw DL, Casteel SW, Frazier D, Rogers K, Tompson RV. Pharmacokinetics of pyropheophorbide-a-hexyl ether in the dog. Lasers Surg Med. 1996; 18: 406-9.
9. Lobel J, MacDonald IJ, Ciesielski MJ, Barone T, Potter WR, Pollina J, et al. 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) in a nude rat glioma model: implications for photodynamic therapy. Lasers Surg Med. 2001; 29: 397-405.
10. Mitra S, Maugain E, Bolotine L, Guillemin F, Foster TH. Temporally and spatially heterogeneous distribution of mTHPC in a murine tumor observed by two-color confocal fluorescence imaging and spectroscopy in a whole-mount model. Photochem Photobiol. 2005; 81: 1123-30.
11. Mitra S, Foster TH. In vivo confocal fluorescence imaging of the intratumor distribution of the photosensitizer mono-L-aspartylchlorin-e6. Neoplasia. 2008; 10: 429-38.
12. Foster TH, Giesselman BR, Hu R, Kenney ME, Mitra S. Intratumor administration of the photosensitizer pc 4 affords photodynamic therapy efficacy and selectivity at short drug-light intervals. Transl Oncol. 2010; 3: 135-41.
13. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140: 883-99.
14. Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer. 2006; 6: 535-45.
15. Korbelik M, Cecic I. Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy. Cancer Lett. 1999; 137: 91-8.
16. De Vree WJ, Essers MC, Koster JF, Sluiter W. Role of interleukin 1 and granulocyte colony-stimulating factor in photofrin-based photodynamic therapy of rat rhabdomyosarcoma tumors. Cancer Res. 1997; 57: 2555-8.
17. De Vree WJ, Essers MC, De Bruijn HS, Star WM, Koster JF, Sluiter W. Evidence for an important role of neutrophils in the efficacy of photodynamic therapy in vivo. Cancer Res. 1996; 56: 2908-11.
18. Gollnick SO, Evans SS, Baumann H, Owczarczak B, Maier P, Vaughan L, et al. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer. 2003; 88: 1772-9.
19. Kousis PC, Henderson BW, Maier PG, Gollnick SO. Photodynamic therapy enhancement of antitumor immunity is regulated by neutrophils. Cancer Res. 2007; 67: 10501-10.
20. Bigelow CE, Conover DL, Foster TH. Confocal fluorescence spectroscopy and anisotropy imaging system. Opt Lett. 2003; 28: 695-7.
21. Manders EMM, Verbeek FJ, Aten JA. Measurement of Colocalization of Objects in Dual-Color Confocal Images. J Microsc-Oxford. 1993; 169: 375-82.
22. Mitra S, Haidaris CG, Snell SB, Giesselman BR, Hupcher SM, Foster TH. Effective photosensitization and selectivity In Vivo of Candida Albicans by meso-tetra (N-methyl-4-pyridyl) porphine tetra tosylate. Lasers Surg Med. 2011; 43: 324-32.
23. Sun J, Cecic I, Parkins CS, Korbelik M. Neutrophils as inflammatory and immune effectors in photodynamic therapy-treated mouse SCCVII tumours. Photochem Photobiol Sci. 2002; 1: 690-5.
24. Henderson BW, Gollnick SO, Snyder JW, Busch TM, Kousis PC, Cheney RT, et al. Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Res. 2004; 64: 2120-6.
25. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol. 2006; 6: 173-82.
26. DiStasi MR, Ley K. Opening the flood-gates: how neutrophil-endothelial interactions regulate permeability. Trends Immunol. 2009; 30: 547-56.
27. Chen B, Pogue BW, Luna JM, Hardman RL, Hoopes PJ, Hasan T. Tumor vascular permeabilization by vascular-targeting photosensitization: effects, mechanism, and therapeutic implications. Clin Cancer Res. 2006; 12: 917-23.
28. Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol. 2011; 11: 519-31.
29. Fleming TJ, Fleming ML, Malek TR. Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. J Immunol. 1993; 151: 2399-408.
30. Nakano H, Yanagita M, Gunn MD. CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J Exp Med. 2001; 194: 1171-8.
31. Rose S, Misharin A, Perlman H. A novel Ly6C/Ly6G-based strategy to analyze the mouse splenic myeloid compartment. Cytometry A. 2012; 81: 343-50.
32. Cummings RJ, Mitra S, Lord EM, Foster TH. Antibody-labeled fluorescence imaging of dendritic cell populations in vivo. J Biomed Opt. 2008; 13: 044041.
33. Abi Abdallah DS, Egan CE, Butcher BA, Denkers EY. Mouse neutrophils are professional antigen-presenting cells programmed to instruct Th1 and Th17 T-cell differentiation. Int Immunol. 2011; 23: 317-26.
34. Iking-Konert C, Cseko C, Wagner C, Stegmaier S, Andrassy K, Hansch GM. Transdifferentiation of polymorphonuclear neutrophils: acquisition of CD83 and other functional characteristics of dendritic cells. J Mol Med (Berl). 2001; 79: 464-74.